CVS Caremark will update its commercial formularies effective July 1, 2026, to prefer FDA-approved interchangeable biosimilars over certain brand-name drugs, including switching from Stelara to biosimilars Pyzchiva and Yesintek. This change aims to reduce drug costs for clients and members, often resulting in $0 out-of-pocket expenses for patients. The update expands biosimilar coverage in specialty areas like multiple sclerosis and rare blood disorders, supporting affordability and access while maintaining clinical quality. CVS Caremark will provide communication and support to ensure a smooth transition for all stakeholders.
At the AHIP 2026 conference, CVS Health highlighted its use of AI to reduce administrative burdens and enhance patient care. Their conversational AI assistant helps members navigate insurance and healthcare processes by anticipating needs and providi...
CVS Health has teamed up with Fluency, an AI platform backed by Accel, to expand the use of autonomous AI agents across its operations. This partnership aims to overcome the common challenge enterprises face in scaling AI from pilot projects to full ...
